Xiidra and Restasis are in a fight.

Shire (maker of Xiidra) is suing Allergan (maker of Restasis).
Shire says that Allergan has blocked access to Xiidra for patients with Part D Medicare plans keeping a nearly $1.5 billion monopoly on the Medicare Part D market.
How could they do that?
According to Shire, Allergan blocked access by “employing egregiously anticompetitive and unlawful tactics.”
The story goes, Shire offered deep discounts on Xiidra in a bid to be covered on Medicare Part D plans but were denied due to Allergan’s “bundled discounts and exclusive dealings” among other things. Shire says they never had a level playing field.
What does Allergan say?
They say they haven’t broken the law and have abided by all the Medicare Part D guidelines. Also, they say this competition is actually driving down pricing which is great for the patient. (via)

Get in Touch


Please enter your comment!
Please enter your name here

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

I agree to these terms.

Related Articles

Latest Posts